Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders

key information

study id #: NCT04907162

condition: Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2, Spinal Muscular Atrophy Type 3, Inclusion Body Myositis, Sporadic, Facioscapulohumeral Muscular Dystrophy 1, Healthy

status: Recruiting


The primary aim is to characterize the prevalence, severity and quality of musculoskeletal nociceptive pain in adult patients with neuromuscular disorders (NMD). The secondary objectives are to evaluate whether severity and distribution of muscle pain is associated with muscle function, and to assess whether muscle pain is associated with alterations of muscle elasticity and muscle stiffness. Results of patients with neuromuscular disorders will be compared to age- and gender-matched healthy volunteers. Approx. 70 patients with neuromuscular disorders and 20 healthy volunteers will be enrolled, including patients with the following neuromuscular disorders: histologically confirmed inclusion body myositis (IBM), genetically confirmed late-onset Pompe disease (LOPD), genetically confirmed spinal muscular atrophy type 3 (SMA3), genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD), genetically confirmed myotonic dystrophy type 1 or type 2 (DM1, DM2). The duration of patient recruitment will be around 12 months.

intervention: Beck depression inventory fast screen, German Pain Inventory, Brief Pain Inventory, Fatigue Severity and Disability Scale (FSS), Quick Motor Function Test, Handheld Dynamometry (HHD), Six-minute walk test (6MWT), Pressure pain threshold, Myotonometer Assessment, Vital signs, Borg Scale


last updated: February 04, 2022